4Moving Biotech (France), Utrecht University (The Netherlands), Chondrometrics GmbH (Germany) and AO Research Institute Davos (Switzerland) have received a EUREKA-Eurostars grant award to finance its €4,2M project (OA-BIO) to complete early clinical development (Phase I) of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), and to identify and validate OA imaging and liquid biopsy biomarkers.
“OA-BIO Eurostars grant represents a unique opportunity to bring together some of the most renowned European teams in the field of OA biomarkers […]”, said Prof. Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), Professor at Sorbonne University (Paris, France) and Director of the INSERM UMR-S938 research.
“OA-BIO […] will advance our understanding on OA biomarkers across the species that typically suffer from OA, like horses and dogs […]”, added Prof. Marianna Tryfonidou, Professor of Regenerative Orthopedics at Faculty of Veterinary Medicine of Utrecht University.
“[…] OA-BIO has a large potential to promote the understanding of the disease and to make a step towards urgently needed therapies”, completed Prof. Felix Eckstein, CEO/CMO of Chondrometrics.
“The OA-BIO consortium breakthrough lies in correlating OA imaging biomarkers with OA molecular ones, […] , as well as to follow how the innovative 4P004 treatment will efficiently interfere with the progression of the OA disease. […]”, concluded Prof. Mauro Alini, Vice-Director of ARI.
4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people suffering from osteoarthritis.
“The incorporation and development of 4Moving Biotech is the proof of the relevancy of 4P-Pharma business model: bringing to patient the best innovations from academic scientists, in a relatively short time and with limited risks. […]”, says Revital Rattenbach, Chairwoman of 4Moving Biotech and 4P-Pharma.
“This fundraising gives us an extraordinary opportunity to conduct our first clinical trial in women and men suffering from OA with 4P004. […]”, adds Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), and Professor at Sorbonne University (Paris, France).
A poster on our latest results on 4P004 entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (#435) will be presented during the OARSI Connect online event on 2021 April 29-May 1, by Pr. Francis Berenbaum (4Moving Biotech’s CEO/CMO, Head of Rheumatology department at Saint-Antoine Hospital, and Professor of Rheumatology at Sorbonne University, in Paris, France).
4P-Pharma received the Seal of Excellence from the European Commission for its application related to the development of a disease modifier treatment for osteoarthritis, 4P-004 to the Horizon 2020 EIC Accelerator (SME instrument).
Following evaluation by an international panel of independent experts, 4P-Pharma’s project was scored as a high-quality proposal in this highly competitive evaluation process, passing all their stringent assessment thresholds for the 3 award criteria (i.e. excellence, impact and implementation).
A poster on 4P-004 entitled “Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies” will be presented during the 3rd International Symposium Research on Healthy Ageing – Longevity Symposium in Institut Pasteur de Lille, France, December 11th-12th 2019, by our Research Assistant, Coralie Meurot (PhD student).
For further information, please feel free to contact our R&D team, Coralie Meurot, Jérôme Breton and Céline Martin via e-mail.
Revital Rattenbach, Présidente de 4P-Pharma, et le Prof. Francis Berenbaum, Professeur de rhumatologie à Sorbonne Université, présentent dans une interview pour “Paroles d’Experts” de la Tribune, 4P-004, une nouvelle molécule thérapeutique visant à enrayer la progression de l’arthrose en vu d’un développement clinique dès 2020.
4P-Pharma, la Biotech au service de l’arthrose
L’arthrose est une maladie qui touche environ 10 % de la population, soit près de 6 millions de Français. En partenariat avec Francis Berenbaum, Professeur de rhumatologie à Sorbonne Université, et la SATT Lutech, la société de biotechnologie 4P-Pharma développe une nouvelle molécule thérapeutique …